XHXuewu Huang

Xuewu Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xuewu Huang has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tumor lysis syndrome in breast cancer: a systematic review of the literature

    by Min Zhang, Junli Li, Linhan Zeng, Yao Chen, Xuewu Huang

    Background: Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency well-characterized in hematologic malignancies but considered rare in solid tumors. In breast cancer, TLS has been documented only in sporadic case reports, and the evolving treatment landscape—including CDK4/6 inhibitors, PI3K inhibitors, novel endocrine agents, and antibody-drug conjugates—may introduce previously unrecognized TLS risks. The only prior review on this topic was published in 2021 and has been superseded by numerous new cases. Methods: We systematically searched PubMed, Embase, and Web of Science from January 2000 to June 2026 for case reports and case series describing TLS in patients with breast cancer, following PRISMA guidelines. TLS diagnosis was verified against Cairo-Bishop criteria. Data on patient demographics, tumor characteristics, precipitating factors, laboratory abnormalities, management, and outcomes were extracted and analyzed descriptively. Results: Twenty cases of TLS from 20 publications were identified, with one additional case of successful TLS prevention. All patients had stage IIB–IV disease, with the majority (90%, 18/20) having stage IV disease; liver metastases were present in 55% (11/20). Precipitating factors included endocrine therapy (n=4, 75% mortality), HER2-targeted therapy (n=4, 50% mortality), chemotherapy (n=6, 50% mortality), radiotherapy (n=2, 50% mortality), PI3K inhibitor (n=1, survived), immunotherapy-chemotherapy combination (n=1, survived), and spontaneous TLS (n=2, 50% mortality). Overall TLS-related mortality was 50% (10/20). Endocrine therapy-associated TLS—predominantly aromatase inhibitors—carried the highest mortality (75%, 3/4). The only surviving patient in this group achieved long-term remission following supportive management. Conclusions: TLS in breast cancer, though rare, carries a high mortality rate approaching 50%. Notably, endocrine therapy—particularly aromatase inhibitors—emerges as a previously underappreciated TLS trigger with disproportionately poor outcomes. With the expanding use of novel targeted and endocrine agents in advanced breast cancer, clinicians should maintain heightened vigilance for TLS, especially in patients with high tumor burden and hepatic metastases. Early recognition and prompt intervention are essential to improve outcomes. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420261429658.

  • Open Access

    Development of a 5-mRNAsi-related gene signature to predict the prognosis of colon adenocarcinoma

    by Haifu Huang, Lin Lu, Yaoxuan Li, Xiumei Chen, Meng Li, Meiling Yang, Xuewu Huang

    Aim To create a prognosis model based on mRNA-based stem index (mRNAsi) for evaluating the prognostic outcomes of colon adenocarcinoma (COAD). Background Generation of heterogeneous COAD cells could be promoted by the self-renewal and differentiation potential of cancer stem cells (CSCs). Biomarkers contributing to the development of COAD stem cells remained to be discovered. Objective To develop and validate an mRNAsi-based risk model for estimating the prognostic outcomes of patients suffering from COAD. Methods Samples were collected from Rectal Adenocarcinoma (TCGA-READ) PanCancer Atlas datasets, The Cancer Genome Atlas Colon Adenocarcinoma (TCGA-COAD), and the GSE87211 dataset. MRNAsi was calculated by one-class logistic regression (OCLR) algorithm. Under the criterion of correlation greater than 0.4, genes related to mRNAsi were screened and clustered. Meanwhile, differentially expressed genes (DEGs) between molecular subtypes were identified to establish a risk model. According to the median risk score value for immunotherapy and results from immune cell infiltration and clinicopathological analyses, clusters and patients were divided into high-RiskScore and low-RiskScore groups. Cell apoptosis and viability were detected by flow cytometer and Cell Counting Kit-8 (CCK-8) assay, respectively. Results A negative correlation between mRNAsi and clinical stages was observed. Three clusters of patients (C1, C2, and C3) were defined based on a total of 165 survival-related mRNAsi genes. Specifically, C1 patients had greater immune cell infiltration and a poorer prognosis. A 5-mRNAsi-gene signature (HEYL, FSTL3, FABP4, ADAM8, and EBF4) served as a prediction index for COAD prognosis. High-RiskScore patients had a poorer prognosis and higher level of immune cell infiltration. In addition, the five genes in the signature all showed a high expression in COAD cells. Knocking down HEYL promoted COAD cell apoptosis and inhibited viability. Conclusion Our mRNAsi risk model could better predict the prognosis of COAD patients.


  • Association between idiopathic pulmonary fibrosis and risk of different pathological types of lung cancer: a Mendelian randomization study

    by Hao Zheng, Duorui Nie, Xuewu Huang

    Background Many epidemiological studies have shown that idiopathic pulmonary fibrosis (IPF) is a risk factor for lung cancer (LC), but these studies do not provide direct evidence of a causal association between the two diseases. We investigated the causal association between IPF and different pathological types of LC based on the Mendelian randomization (MR) study. Methods The genome-wide association study (GWAS) data of IPF and LC were obtained from the latest published articles, and instrumental variables (IVs) for analysis were obtained after screening and eliminating the confounders. MR Analysis was carried out with the help of random effects inverse variance weighting (re-IVW), MR-egger, and weighted median method, and a comprehensive sensitivity test was conducted. Results The results of re-IVW analysis showed that IPF may increase the risk of lung squamous cell carcinoma (LUSC) (OR = 1.045, 95% CI 1.011 to 1.080, P = 0.008). In addition, no causal relationship was found between IPF and overall LC (OR = 0.977, 95% CI 0.933 to 1.023, P = 0.32), lung adenocarcinoma (LUAD) (OR = 0.967, 95% CI 0.903 to 1.036, P = 0.345) and small cell lung carcinoma (SCLC) (OR = 1.081, 95% CI 0.992 to 1.177, P = 0.074). A comprehensive sensitivity analysis ensured the reliability of the study. Conclusion In conclusion, from the perspective of genetic association, we found that IPF is an independent risk factor for LUSC and may increase the risk of LUSC, but no such causal relationship was found in LUAD and SCLC.


  • Open Access

    The Prognostic Value of Serum Apolipoprotein A-I Level and Neutrophil-to-Lymphocyte Ratio in Colorectal Cancer Liver Metastasis

    by Chongkai Fang, Yue Huang, Chuyao Chen, Duorui Nie, Jietao Lin, Zhiwei Xiao, Saimei Li, Silin Liu, Rui Luo, Hongtong Lin, et al.

    Background. Colorectal cancer liver metastasis (CRLM) is a high degree of malignancy with rapid disease progression and has a poor prognosis. Both serum apolipoprotein A-I (ApoA-I) and neutrophil-to-lymphocyte ratio (NLR) play key roles in anti-inflammation and antitumor. This study is aimed at evaluating the implication of serum ApoA-I level in combination with NLR in the prognosis of CRLM. Methods. We retrospectively analyzed the serum ApoA-I level and NLR in 237 patients with CRLM. Cox regression analyses were used to identify the independent prognostic significance of these indicators. Kaplan-Meier method and Log-rank test were applied to compute overall survival (OS). Both the ApoA-I and NLR were divided into three levels, according to their medians. A risk-stratified prediction model was established to evaluate the prognosis of patients with CRLM. The ROC curve AUC values were applied to evaluate the capability of the model. Results. Higher levels of ApoA-I and lower NLR were strongly associated with prolonged OS (Log-rank test, P < 0.05 ). The patients were then grouped into three queues according to the ApoA-I level and NLR. There was a crucial diversity in the OS ( P < 0.001 ) between the high-risk ( ApoA − I ≤ 1.03 g/L and NLR > 3.24 ), medium-risk ( ApoA − I > 1.03   g/L or NLR ≤ 3.24 ) and low-risk groups ( ApoA − I > 1.03   g/L and NLR ≤ 3.24 ). The AUC value of the prediction model ( AUC = 0.623 , 95% CI: 0.557-0.639, P = 0.001 ) was higher than other individual indicators (including ApoA-I, NLR, cT classification, and cN classification). Additionally, the association of the prediction model and cTN classification ( AUC = 0.715 , 95% CI: 0.606-0.708, P < 0.001 ) was better than the model and cTN classification alone. Conclusion. The combination of ApoA-I level and NLR could be a prognostic indicator for CRLM.


  • Open Access

    Metastatic Colorectal Cancer Patient With Microsatellite Stability and BRAFV600E Mutation Showed a Complete Metabolic Response to PD-1 Blockade and Bevacizumab: A Case Report

    by Chongkai Fang, Jietao Lin, Tao Zhang, Jiajun Luo, Duorui Nie, Meng Li, Xue Hu, Yating Zheng, Xuewu Huang, Zhiwei Xiao

    A vast majority of colorectal cancer (CRC) patients with microsatellite stability (MSS) or proficient mismatch repair (pMMR) are refractory to immunotherapeutic strategies. The current research focusses on the combined treatment strategies for identification and optimization in order to improve the efficacy of immunotherapy among patients with microsatellite stability (MSS), who account for the majority of metastatic colorectal cancer (mCRC) cases. mCRC patients harboring MSS and the BRAFV600E mutation show a worse prognosis and barely benefit from immunotherapy. In this report, we discuss the case of a mCRC patient with MSS and BRAFV600E mutation, who exhibited significant response to the combined treatment with nivolumab and bevacizumab, and has been exhibiting a progression-free survival (PFS) of more than 17 months. Our findings indicate that combined anti-angiogenic therapy can improve the efficacy of immunotherapy, which results in the prolong survival of the patient. This is a case report on MSS and BRAFV600E colorectal cancer which presents with a response to immunotherapy and anti-angiogenic therapy.


  • Open Access

    The contemporary trend in worsening prognosis of pancreatic acinar cell carcinoma: A population-based study

    by Nie Duorui, Bin Shi, Tao Zhang, Chuyao Chen, Chongkai Fang, Zhijun Yue, Peng Wu, Zhiming Wu, Xuewu Huang, Meng Li

    Background: Primary acinar cell carcinoma (ACC) is a rare exocrine tumor of the pancreas with unclear clinical characteristics. Our goal was to determine the incidence and update the clinical characteristics and outcomes of ACC.Methods: Through the Surveillance, Epidemiology, and End Results (SEER) database, we identified 252 patients with the latest diagnosis of ACC (2004–2016). The age-adjusted incidence (AAI) was calculated using the SEER*Stat Software version 8.3.6. The Kaplan–Meier method was used to draw survival curves and differences among them were compared by the log-rank test. Cox proportional hazards models were used to evaluate factors that had independent predictive effects on the overall survival.Results: The AAI of pancreatic ACC was on the rise with the mean age at diagnosis of 63.79±14.79 years. Most patients (15.9%) had poorer differentiated tumors. The patients presented with distant stage were 54.4% compared with 53.1% between 1988 and 2003. The 1-, 2-, and 5-years survival rates for pancreatic ACC patients were 53.5%, 34.6%,17.5%, respectively (compared with 78.5%, 67.0%, and 42.8%, between 1988 and 2003). The multivariate COX analysis showed that the patient's age, surgery, chemotherapy, and summary stage, but not marital status were independent prognosis factors for ACC.Conclusions: Pancreatic ACC is a highly malignant tumor with an increasing incidence in recent years. The rate of distant metastasis is increasing and the survival rate is worse than in the past, suggesting that it may require more aggressive treatment and follow-up. Surgery, radiotherapy, and chemotherapy are all effective treatments, but prospective studies are still needed to verify them.


  • Open Access

    Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial

    by Zhiwei Xiao, Leihao Hu, Jietao Lin, Liming Lu, Xuewu Huang, Xiaoshu Zhu, Chiahshean Teo, Lizhu Lin

    Background: Chemotherapy-related fatigue (CRF) is a common symptom in non-small cell lung cancer (NSCLC) patients. A Chinese herbal formula cream for oral application, called Jianpishengsui (JPSS), is extensively used in the First Affiliated Hospital of Guangzhou University of Chinese Medicine as an internal preparation for CRF and is associated with a promising response. Due to the lack of high-quality clinical evidence, a randomized placebo-controlled trial is required to assess the efficacy and safety of JPSS. Methods/design: The efficacy and safety of JPSS herbal formula cream will be evaluated through a prospective, randomized, placebo-controlled trial conducted in the First Affiliated Hospital of Guangzhou University of Chinese Medicine. NSCLC patients with CRF will be randomized into two groups at a ratio of 1:1. Each group will receive either 15 g of the oral JPSS herbal formula cream or placebo twice a day from day 6 to day 20 during two courses of paclitaxel + platinum/docetaxel + platinum/pemetrexed + platinum (TP/DP/AP) chemotherapy. The primary endpoint is the difference in the degree of fatigue between baseline (the day before the start of the intervention) and day 42, which will be assessed by the Revised Piper Fatigue Scale score. The secondary endpoints are quality of life (measured by the 43-item European Organization for Research and Treatment of Cancer Quality of Life Questionnaire—Lung Cancer C43), Eastern Cooperative Oncology Group Performance Status, and Traditional Chinese Medicine syndrome score. The toxicity of the treatments will also be evaluated at the same time. All outcomes will be measured at baseline, day 6, day 21, and day 42 of the treatment. Discussion: This randomized trial will investigate the efficacy and safety of JPSS applied for CRF in patients with NSCLC. Trial registration: Chinese Clinical Trial Registry, ChiCTR1900023451. Registered on 28 May 2019.


  • Open Access

    Treatment of syncope in tongue cancer with palliative chemotherapy in the intensive care unit

    by Chongkai Fang, Liting Yang, Guangbi Zeng, Ruilin Huang, Wei Fang, Yao Chen, Jieshan Guan, Peng Li, Xuewu Huang, Lizhu Lin

    Rationale: Syncope caused by head and neck cancer (HNC) is rare. However, syncope caused by tongue cancer (TC) is even rarer. In TC, syncope is caused by tumor-mediated compression of the carotid sinus and stimulation of the glossopharyngeal nerve. Patient concerns: In this study, we report the case of a 48-year-old male patient who was diagnosed with advanced TC and bilateral cervical lymph node metastasis. On the third day of admission, the patient experienced recurrent syncope with hypotension and bradycardia. Diagnoses: The patient was diagnosed with a well-differentiated squamous cell carcinoma of the tongue along with massive cervical lymph node metastasis and carotid sinus syndrome. Interventions: Initially, symptomatic treatment of syncope boosted the blood pressure and increased the heart rate. Thereafter, a temporary pacemaker was implanted. Finally, chemotherapy was used to control the tumor and relieve syncope. Outcomes: After chemotherapy, the tongue ulcers and cervical lymph node reduced in size; syncope did not recur. Lessons: This case shows that chemotherapy may be a valid treatment option in patients with cancer-related syncope; however, the choice of chemotherapeutic drugs is critical. Intensive care provides life support to patients and creates opportunities for further treatment.


  • Open Access

    Expression of miR‑21 and miR‑138 in colon cancer and its effect on cell proliferation and prognosis

    by Changxuan You, Liming Jin, Qi Xu, Bo Shen, Xuelong Jiao, Xuewu Huang

    Effect of miR‑21 and miR‑138 on the proliferation of colon cancer cells and their association with prognosis were investigated. Expression levels of miR‑21 and miR‑138 in colorectal cancer and normal adjacent tissues were compared. Differential expression of miR‑21 and miR‑138 in colon cancer tissues with different clinicopathological features were analyzed. miR‑21 and miR‑138 expression vectors were established and transfected into cells of colon cancer cell line SW480. Methyl thiazolyl tetrazolium (MTT) assay was used to detect the proliferation of SW480 cells. Kaplan‑Meier method and log‑rank test were used to study the relationship between miR‑21 and miR‑138 expression and prognosis. Cox proportional hazards model was used to analyze the factors related to prognosis of colon cancer. Expression level of miR‑21 in colon cancer tissues was significantly higher than that in adjacent tissues, and expression level of miR‑138 was lower in cancer tissues than in adjacent tissues (P<0.001). Expression of miR‑21 and miR‑138 was associated with the degree of differentiation, lymph node metastasis, distant metastasis, and TNM stage (P<0.05). miR‑21 promotes proliferation of colon cancer cell line SW480, and miR‑138 inhibits cell proliferation. Survival analysis showed that the survival time of patients with high expression of miR‑21 was significantly shorter than that of patients with low expression of miR‑21, while survival time of patients with high expression of miR‑138 was significantly longer than that of patients with low expression of miR‑138 (log‑rank, P<0.05). miR‑21 is highly expressed in colon cancer tissues and is positively associated with the degree of malignancy of patients but negatively associated with survival. miR‑138 expression is low in colon cancer tissues and is negatively associated with the degree of malignancy of patients but positively associated with survival. miR‑21 and miR‑138 may be involved in the regulation of colon cancer cell proliferation.